EVGN logo

Evogene Ltd. Stock Price

TASE:EVGN Community·₪25.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

EVGN Share Price Performance

₪2.55
-1.26 (-33.08%)
₪2.55
-1.26 (-33.08%)
Price ₪2.55

EVGN Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks
1 Reward

Evogene Ltd. Key Details

US$3.9m

Revenue

US$4.1m

Cost of Revenue

-US$241.0k

Gross Profit

US$13.9m

Other Expenses

-US$14.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.43
-6.25%
-367.43%
0%
View Full Analysis

About EVGN

Founded
1999
Employees
117
CEO
Ofer Haviv
WebsiteView website
www.evogene.com

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Recent EVGN News & Updates

Recent updates

No updates